Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

NanoViricides, Inc. Common Stock (NY:NNVC)

1.409 +0.009 (+0.67%)
Streaming Delayed Price Updated: 12:37 PM EDT, Jul 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NanoViricides, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights NV-387 as Broad-Spectrum Antiviral Candidate for COVID and Bird Flu Preparedness
Via Investor Brand Network
Topics Intellectual Property
With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Advances Measles Drug Program Amid Rising Global Outbreaks
Via Investor Brand Network
Topics Intellectual Property
NanoViricides, Inc. Has Filed its Quarterly Report
Via ACCESS Newswire
NanoViricides Measles Drug Development Animal Study is Imminent
Via ACCESS Newswire
NanoViricides (NNVC) to Unveil ‘Escape-Proof’ Antiviral Platform at Major Biotech Convention
Via AB Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) to Present Breakthrough Antiviral Platform at BIO International Convention
Via Investor Brand Network
Topics Intellectual Property
NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Comments on FDA COVID Booster Policy, Highlights Antiviral Strategy
Via Investor Brand Network
Topics Intellectual Property
The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Advances NV-387 Antiviral Program, Prepares for Multiple Phase II Trials
Via Investor Brand Network
Topics Intellectual Property
NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa - Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Advances NV-387 Antiviral as Measles and MPox Resurge Globally
Via Investor Brand Network
Topics Intellectual Property
Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Clears Ethics Review for Phase II Mpox Trial in DRC
Via Investor Brand Network
Topics Intellectual Property
Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) to Present at D. Boral Capital Inaugural Global Conference
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Advances Measles Drug Development with Broad-Spectrum Antiviral NV-387
Via Investor Brand Network
Topics Intellectual Property
Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It
Via ACCESS Newswire
Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Antiviral Pipeline, Positions Stock as Market Hedge
Via Investor Brand Network
Topics Intellectual Property World Trade
NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights NV-387 as Potential Measles Treatment Amid Outbreak
Via Investor Brand Network
Topics Intellectual Property
Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Reports Financials, Advances NV-387 Antiviral Trials
Via Investor Brand Network
Topics Intellectual Property Regulatory Compliance
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Claims NV-387 Ready to Combat Bird Flu
Via Investor Brand Network
Topics Intellectual Property
NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Showcases NV-387’s Broad-Spectrum Antiviral Potential at MicroCap Conference
Via Investor Brand Network
Topics Intellectual Property
NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025
Via ACCESS Newswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.